Abstract | OBJECTIVE: METHODS AND RESULTS: sPLA2-IIA mass and sPLA2 activity were measured at baseline and after two years in 187 children with FH (aged 8-18 years) randomized to pravastatin or placebo. At baseline, median [IQR] sPLA2-IIA mass and sPLA2 activity levels were 7.2 [5.8-13.2] ng/ml and 36.4 [29.8-47.1] U/ml, respectively. Both sPLA2-IIA mass and sPLA2 activity were significantly correlated with high-sensitivity C-reactive protein (r = 0.33, p < 0.001 and r = 0.386, p < 0 .001, respectively), but not with other cardiovascular risk factors. Baseline levels of sPLA2-IIA mass and sPLA2 activity were not significantly associated with carotid intima-media thickness (cIMT) at baseline or at the end of follow-up. After two years, sPLA2-IIA mass and sPLA2 activity levels were not significantly reduced in the pravastatin group (p = 0.20 and p = 0.63, respectively), nor in the placebo group (p = 0.17 and p = 0.11, respectively). Changes from baseline did not differ between the treatment groups for sPLA2-IIA mass (p = 0.48) and sPLA2 activity (p = 0.88). CONCLUSIONS: sPLA2-IIA mass and sPLA2 activity were not significantly associated with cIMT in our pediatric FH cohort. This could indicate that the potential predictive role of sPLA2 as a biomarker of cardiovascular disease in children with FH is limited. Treatment with pravastatin did not reduce sPLA2-IIA mass or sPLA2 activity levels, as compared to placebo. Further studies with larger samples are required to address these issues.
|
Authors | Marjet J A M Braamskamp, Sotirios Tsimikas, Albert Wiegman, John J P Kastelein, Barbara A Hutten |
Journal | Atherosclerosis
(Atherosclerosis)
Vol. 229
Issue 2
Pg. 404-7
(Aug 2013)
ISSN: 1879-1484 [Electronic] Ireland |
PMID | 23880195
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | Copyright © 2013 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Biomarkers
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- C-Reactive Protein
- Phospholipases A2, Secretory
- Pravastatin
|
Topics |
- Adolescent
- Biomarkers
(blood)
- C-Reactive Protein
(metabolism)
- Carotid Intima-Media Thickness
- Child
- Double-Blind Method
- Female
- Follow-Up Studies
- Heterozygote
- Humans
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
(administration & dosage)
- Hyperlipoproteinemia Type II
(blood, drug therapy, genetics)
- Male
- Phospholipases A2, Secretory
(blood)
- Pravastatin
(administration & dosage)
- Predictive Value of Tests
|